The Effects of Almond Consumption on Functional Performance and Activity in Overweight Active Older Adults

• ClinicalTrials.gov Identifier: NCT04778371
• Recruitment Status: Recruiting
• First Posted: March 3, 2021
• Last Update Posted: October 6, 2021
• Sponsor: Florida State University
• Collaborator: Almond Board of California
• Information provided by (Responsible Party): Bahram Arjmandi, Florida State University

Study Description

Brief Summary:

The overall objective of this proposed randomized, crossover study is to determine the effect of 12 weeks of almond consumption, ingested as a snack twice daily, on energy expenditure, performance and functional related outcomes, in active, overweight, older adults, in comparison to 12 weeks of an isocaloric matched control snack. The central hypothesis of this study is, due to the nutritionally beneficial composition of almonds, that daily consumption of an almond snack for 12 weeks will contribute to improvements in energy expenditure, physical and functional performance, vascular function, inflammation/oxidative stress, sleep quality, mood status, and body composition in active, overweight and obese older adults compared to an isocaloric commercially available snack.

Condition or disease	Intervention/treatment	Phase
Overweight	Other: Almonds; Other: Placebo	Not Applicable

Detailed Description:

By 2030 it estimated that 20% of individuals in the United States (U.S.) will be 65 years of age or older, indicating a shift in demographics over the past century. The aging process is strongly associated with reduced aerobic capacity and functional performance as well as increases in inflammation and oxidative stress. With differences in the demographic profile, eating patterns have also changed for Americans within the past 30 years, with a majority of Americans consuming at least one snack/day; with the types of snacks consumed being processed foods that are high in refined carbohydrates, saturated fats, and low in fiber. Additionally, the aging process contributes to decreases in RMR, which can promote alterations in body composition. Lifestyle modifications have been shown to contribute to beneficial outcomes associated with aging. Therefore, healthy, nutrient-dense foods are of primary importance for enhancing functional performance, aerobic capacity, and physical activity as well as improving vascular function, body composition, and markers of inflammation/oxidative stress within this growing population. Tree nuts are a nutrient- and energy dense food, which may contribute to increases in RMR due to their high amounts of poly- and monounsaturated fatty acids affecting diet-induced thermogenesis. Almonds (Prunus dulcis) are an excellent source of α-tocopherol and a good source of monounsaturated fat, magnesium, fiber, and protein. When compared to other nuts almonds have the greatest amount of fiber and protein. Almond supplementation has been shown to attenuate age-related decline in aerobic fitness and physical performance measures. Few studies have assessed how almonds alone affect fitness and physical function. However, Yi et al. found that in young healthy, endurance trained individuals, consumption of almonds elevated serum arginine, nitric oxide and TAC, all of which contributed to improved exercise performance. Constituents of almonds including L-arginine and magnesium have been shown to increase anaerobic threshold and physical performance in healthy active older adults respectively . Studies have found that the incorporation of almonds in a diet can decrease oxidative stress and improve vascular function. Improvements in both FMD and systolic blood pressure were shown after 4 weeks of almond consumption in healthy old and young men. L-arginine, an amino acid vital for synthesis of nitric oxide, which controls vascular tone, is also found in almonds. Almonds are often cited as a healthy, protein-boosting snack, beneficial for sustaining muscle mass and metabolism, without increasing fat mass or total energy intake. Additionally, studies have demonstrated that body weight and body mass index (BMI) remain unchanged during almond supplementation interventions. Almond consumption has also been shown to decrease visceral fat and body fat percentage. The extent to which daily almond consumption affects functional performance, aerobic capacity, energy expenditure, vascular function, body composition and inflammation/oxidative stress in active overweight and obese older adults needs to be investigated.

For this study, fifty men and postmenopausal women will follow a randomized-controlled crossover design. If individuals qualify for participation after the screening visit, they will be asked to complete a 3-day food record and wear an ActiGraph to track physical activity and sleeping patterns for the next seven days, to be returned at their Baseline Study Visit #1. During the Baseline Study Visit #1 assessments of: RMR, body composition (DXA), vascular assessments (FMD, PWV, PWA, blood pressure), heart rate, anthropometrics (height, weight, and waist/hip circumference), venous blood draw, POMS, and sleep quality (PSQI) will be collected. The following day, participants will return for their Baseline Physical Performance Visit #1 to complete assessments of submaximal aerobic capacity and the CS-PFP. Following this visit, participants will be provided with 12 weeks of almonds or the isocaloric snack. Participants will be asked to come in after 6 weeks to receive the rest of their dietary regimen and to monitor compliance. During week 11, participants will be asked to come to the study site to be given a 3-day food record and the ActiGraph to be retuned at the Post-Test Study Visit #1. After 12 weeks, participants will return to FSU to complete their Post-Test Study Visit #1, which will involve all the same assessments from the baseline study visit, as well as their Post-Test Physical Performance Visit #1, the next day. After the 4-week washout period, participants will similarly be asked to complete a 3-day food record and wear an ActiGraph for the following 7 days, to be returned upon the participants' Baseline Study Visit #2, where participants will crossover into receiving the corresponding dietary regimen and will follow the same procedures for the following 12 weeks. Participants will be compensated a total of $200 if the entire study is completed.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 50 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: Randomized, calorie-match controlled, crossover design
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: The Effects of Almond Consumption on Functional Performance, Aerobic Capacity, and Physical Activity in Overweight Active Older Adults
• Actual Study Start Date: March 2, 2021
• Estimated Primary Completion Date: October 20, 2022
• Estimated Study Completion Date: December 20, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Almond supplement; Participants will consume 32 g dry roasted, unsalted almonds twice a day for 12 weeks	Other: Almonds; 64 g total dry roasted, unsalted almonds per day for a total of 12 weeks
Placebo Comparator: Placebo matched supplement; Participants will consume 100 g granola bar, calorie matched to Almond, twice a day for 12 weeks	Other: Placebo; 200 g total calorie matched granola bar per day for total of 12 weeks

Outcome Measures

Primary Outcome Measures :

1. Effect of almonds on functional performance [ Time Frame: 1 year ]

   Functional performance assessed by the Continuous-Scale Physical Functional Performance Test

   • 5 Domain scores each scored on scale of 0-100:
   • upper-body strength
   • lower body strength
   • upper body flexibility
   • balance and coordination
   • endurance
2. Effect of almonds on submaximal aerobic capacity (VO2) [ Time Frame: 1 year ]
   • treadmill test ends at 85 % max VO2 measured using ParvoMedics metabolic cart
   • Range: approx 20 ml/kg/min to 60 ml/kg/min
   • Higher value the better (more aerobically fit)

Secondary Outcome Measures :

1. Effect of almond on respiratory exchange ratio (RMR) [ Time Frame: 1 year ]
   • respiratory exchange ratio as measured using the Parvomedics Metabolic Cart
   • measures resting energy expenditure
2. Effect of almond on body fat [ Time Frame: 1 year ]

   measured by duel energy x-ray absorptiometry

   -

3. Effect of almond on lean body mass [ Time Frame: 1 year ]

   measured by duel energy x-ray absorptiometry

   -

4. Effect of Almond on sleep pattern [ Time Frame: 1 year ]

   Actigraph watch worn for 1 week prior to baseline and post-tests

   -monitors sleep activity

5. Effect of Almond on arterial health [ Time Frame: 1 year ]

   Measured using flow mediated dilation via Philips HD11XE Doppler Ultrasound

   • Measures the ability of an artery to respond to an increase in blood flow via vasodilation
   • Brachial artery will be examined using a linear array transducer
6. Effect of Almond on arterial health [ Time Frame: 1 year ]
   • Measured via pulse wave velocity (PWV) using PWV Automatic Device (VP-2000, Omron Healthcare Inc.)
   • PWV is the velocity at which the blood pressure pulse is conducted through the circulatory system via an artery or a combined series and length of arteries)
   • Used to measure arterial stiffness
   • Measured in m/sec
7. Effect of Almond on oxidative stress [ Time Frame: 1 year ]
   Measured via fasting blood draw 20 ml
8. Effect of almond on inflammation [ Time Frame: 1 year ]
   Measured via fasting blood draw 20 ml

Eligibility Criteria

• Ages Eligible for Study: 50 Years to 59 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• 50 physically active men and postmenopausal women (free of menstruation for 12 consecutive months)
• Between the ages of 50-59 years
• Free of any chronic diseases such as cancer
• Active lifestyle (>30 minutes, 3 days/week)
• BMI of 25.0 kg/m2 to 29.9 kg/m2 will be included
• There will be no restrictions based on race, ethnicity, or socioeconomic status.

Exclusion Criteria:

• Individuals diagnosed with cardiovascular diseases (CVD) Type 2-diabetes
• Uncontrolled hypertension (≥160/100 mmHg)
• BMI <25.0 kg/m2 or >29.9 kg/m2
• Other active chronic diseases such as cancer, asthma, glaucoma, kidney, liver and pancreatic disease
• Those who are not post-menopausal or on hormone replacement therapy
• Taking more than one anti-hypertensive or have been taking them for less than 3 months -Any musculoskeletal or orthopedic problem that would otherwise prevent completing the study Participants participating in a weight loss program or having lost or gain ≥10% bodyweight within the last 6 months
• Currently using tobacco
• Consumption of >12 alcoholic drinks/week
• Nut allergies
• Frequent tree nut consumers (>2 servings/week)
• In concurrent participation with another investigational study
• Currently consuming any performance supplement (i.e. creatine, nitric oxide, whey/casein protein, branched chain amino acids).

Contacts and Locations

Contacts

Contact: Bahram Arjmandi, PhD; 850-645-1517; barjmandi@fsu.edu

Contact: lauren ormsbee, M.S.; 850-644-4889; lormsbee@fsu.edu

Locations

United States, Florida

Florida State University; Recruiting

Tallahassee, Florida, United States, 32306

Contact: Bahram Arjmandi, PhD 850-645-1517 barjmandi@fsu.edu

Sponsors and Collaborators

Florida State University

Almond Board of California

More Information

• Responsible Party: Bahram Arjmandi, Professor Bahram Arjmandi, PhD, RD, Principal Investigator, Florida State University
• ClinicalTrials.gov Identifier: NCT04778371
• Other Study ID Numbers: 00001394
• First Posted: March 3, 2021
• Last Update Posted: October 6, 2021
• Last Verified: October 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Bahram Arjmandi, Florida State University:

almond; functional performance; aerobic capacity; physical activity

Additional relevant MeSH terms:

Overweight; Body Weight